Q3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches review
From BioSpace · · 23 min
This plays from the publisher's own server. We do not host a copy.
Not rated yet
Description
The majority of the large pharmas have now reported third quarter earnings—spoiler alert: Eli Lilly made more money than anyone expected. Plus, the FDA dropped another initiative aimed at accelerating rare disease treatments; HHS greenlights the compounding of six unapproved peptides; and uniQure’s embattled gene therapy for Huntington’s disease has finally been accepted for review.